Precision Medicine of Hepatobiliary and Pancreatic Cancers: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Lindsay Dong and Version 1 by Takehiko Tsumura.

Precision medicine involves comprehensive genome profiling (CGP) using next-generation sequencing (NGS), which is clinically performed worldwide to find a drug suitable for each patient. The aim of precision medicine is to identify and target those genome-wide alterations in various cancers, and the genetic changes identified by NGS technologies support personalized drug design for patients with specific genetic alterations.

  • precision medicine
  • next-generation sequencing
  • hepatobiliary cancer
  • pancreatic cancer

1. Introduction

Cancer is a genetic disease caused by a stepwise accumulation of genetic alterations. Revolutionary high-throughput sequencing capacity of next-generation sequencing (NGS) technologies supported a breakthrough in cancer genome research and accelerated the innovation in anti-cancer drug development. Several genetic alterations have been discovered in human cancerous tissues using NGS-based whole-exome and whole-genome sequencing. Precision medicine involves comprehensive genome profiling (CGP) using NGS, which is clinically performed worldwide to find a drug suitable for each patient. For example, in bile duct cancers, genetic aberrations in tumor protein P53 (TP53); Kirsten rat sarcoma virus (KRAS); phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PI3KCA); BAP1; cyclin-dependent kinase inhibitor (CDKN)2A/B; AT-rich interaction domain 1A (ARID1A); receptor tyrosine-protein kinase erbB-2 (ERBB2); proto-oncogene B-Raf (BRAF); fibroblast growth factor receptor (FGFR)1–3; isocitrate dehydrogenase (IDH)1/2; MET proto-oncogene, receptor tyrosine kinase (MET); and FGFR2 are frequently detectable and used as major markers for selective therapies [1,2][1][2]. In pancreatic cancers, frequent mutations of several cancer-related genes, such as KRAS, TP53, CDKN2A, SMAD family member 4 (SMAD4), CDKN2B, ARID1A, GATA6, and MYC, have been determined using NGS [3]. Additionally, in hepatocellular carcinoma (HCC), genetic alterations have been found in telomerase reverse transcriptase (TERT), p53/RB (TP53 and CDKN2A), or Wnt/βcatenin (CTNNB1 and AXIN1) signaling pathways [4,5][4][5].

2. Precision Medicine Targets in Biliary Tract Cancer (BTC)

BTC is a well-targeted cancer type addressed by precision medicine. The European Society for Medical Oncology precision medicine working group guidelines recommended that CGP should be investigated using NGS in this cancer [22][6]. Genomic findings differ for the three BTC types, including intrahepatic cholangiocarcinoma (IHCCA), extrahepatic cholangiocarcinoma (EHCCA), and gallbladder cancer (GBCA). Gene mutations of FGFR1–3, TP53, IDH1/2, ARID1/2, CDKN2A/B, and KRAS were found in IHCCA [1,2][1][2]. Changes in KRAS, TP53, and SMAD4 were detected in EHCCA [1,2][1][2]. Important alterations in TP53, ERBB2/3, CDKN2A/B, ARID1A, and KRAS have also been reported in GBCA [1,2][1][2].

2.1. IDH1

IDH is an enzyme that regulates energy metabolism in the citric acid cycle. Wild-type IDH1 contributes to the reaction, producing α-ketoglutaric acid from isocitric acid. Mutant IDH1 produces D-2-hydroxyglutarate (D-2-HG), an oncometabolite. D-2-HG competitively inhibits IDH1 enzyme activity that depends on α-ketoglutaric acid, causing carcinogenesis [23][7]. About 16% of patients with IHCC have IDH1 mutations [1]. Ivosidenib is a novel small molecule inhibitor of mutant IDH1 protein. ClarIDHy is an international phase 3 study that proved the efficacy of ivosidenib against BTC with IDH1 mutation. PFS, which was the primary study endpoint, was 2.7 months (95% CI: 1.6–4.2 months) and 1.4 months (95% CI: 1.4–1.6 months) for ivosidenib and placebo groups, respectively [8].

2.2. Fibroblast Growth Factor Receptor (FGFR)2 Fusion

FGFs are growth factors comprising 23 family members, which can bind to FGFR1–4 as ligands. FGFR2 fusion genes are known as driver oncogenes [24,25][9][10]. The prevalence of FGFR2 mutations in IHCCA was reported as 5–15%. At least 19 fusion partners were identified and contained functional domains related to the formation of a dimer or multimer. Generated from the fusion gene, FGFR2 forms a dimer which is activated without ligand stimulation, causing oncogenesis [24,25][9][10].

2.3. EGFR (HER)2 Amplification

HER2 (encoded by ERBB2 gene) is a membrane-penetrating receptor tyrosine-protein kinase. After the attachment of a specific ligand, the receptor forms a heterodimer and triggers growth-stimulating intracellular signaling. Overexpression or mutation of HER2 continuously activates the mitogen-activated protein kinase (MAPK) and PI3K/AKT pathways independently without a ligand. Therefore, HER2 overexpression/mutations are often associated with tumor proliferation or inhibition of apoptosis [26,27,28,29,30,31][11][12][13][14][15][16]. ERBB2 amplification was rarely found in IHCCA(3%) but was more common in EHCCA (11%) and GBCA (16%) [1].

2.4. BRAF V600E

BRAF (A, B, and C subtypes) protein is a serine/threonine kinase associated with the MAPK pathway [32,33,34][17][18][19]. The binding of BRAF ligands forms a dimer, which transmits signals downstream of the MAPK network. Mutated BRAF could play a role as oncogenes. BRAF mutants activate downstream growth-promoting signals continuously, causing oncogenic transformation. The most common oncogenic BRAF mutation is BRAF V600E [35][20]. BRAF mutation frequency was reported at 5% in BTC [1]. BRAF V600E is one of the tumor-agnostic targets of precision medicine. The ROAR basket trial indicated that the combination therapy with dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) was effective against the BRAF V600E-mutated BTC [14][21].

3. Precision Medicine Targets in Pancreatic Ductal Adenocarcinoma (PDAC)

PDAC has a comparatively uniform genetic background comprising four mutated genes: KRAS, CDKN2A [p16/p14], TP53, and SMAD4 [3]. Although genetic alterations were frequently observed in ARID1A, KMT2C, RNF43, FAT3, and KMT2D [3], KRAS, BRCA2, and NRG1 are considered more valuable in cancer diagnostic using precision medicine for PDAC [3].

3.1. BRCA1/2

PDAC represents a phenotype of hereditary breast and/or ovarian cancer syndrome, the well-known hereditary tumor syndrome caused by the BRCA1/2 mutation. The main phenotypes are breast and ovarian cancers, as its name suggests. Instances of prostate and other cancers have also been reported in carriers of the mutation [36,37,38][22][23][24]. BRCA mutation causes decompensation of double-strand DNA break repair—homologous recombination repair deficiency. Poly (ADP-ribose) polymerase (PARP) inhibitor, which inhibits single-strand DNA break compensation, can activate apoptosis in cancer cells with BRCA1/2 mutation and increase anti-cancer platinum sensitivity. However, only 6% of metastatic PDACs had BRCA1/2 mutations [15][25].

3.2. KRAS G12C

KRAS mutation is a significant oncogenic mutation and is found in 95% of PDACs. RAS is activated by connecting with GTP, receiving the signal from receptor tyrosine kinase. Activated RAS transmits the proliferation-promoting signal to the downstream MAPK pathway effectors. RAS, which has GTPase function, converts GTP into GDP via hydrolysis and proceeds to its inactivated state. However, mutated RAS has weak GTPase activity and induces a prolongation of activated signaling downstream, contributing to a malignant trait. Several efforts have been made to develop drugs that target mutated RAS. The effectiveness and safety of sotorasib, which affect mutated KRAS G12C, have been assessed in a phase 1/2 study named CodeBreaK 100 trial [18][26].

3.3. Neuregulin (NRG)1

NRG1 is now gaining attention as a new target for precision medicine among KRAS-negative PDACs [44,45][27][28]. NRG1 protein is a cell adhesion molecule that belongs to the NRG family and affects the epidermal growth factor receptor (EGFR). The epidermal growth factor (EGF)-like domain of NRG1 regulates itself or nearby cells using HER2s or HER3/HER4 dimers. About 0.5% of PDAC have NRG fusion, and the specific fusion partners in PDAC are CDH1, ATP181, and VTCN1 [19][29]. The efficacy of zenocutuzumab, an NGR inhibitor, is proved in the phase 1/2 global open-label clinical trial (eNRGy) and the early access program against NSCLC and PDAC showing NRG1 fusion.

4. Possible Targets for Precision Medicine of Hepatocellular Carcinoma (HCC)

The accumulation of gene aberrations induced by several risk factors, such as alcohol, hepatitis virus infection, or steatohepatitis, causes hepatocarcinogenesis. Genetic alterations in TERT, TP53, or Wnt/βcatenin signaling pathway could play a role as a cancer driver for HCC. Genetic analysis of 755 HCC patients using NGS revealed genetic aberrations in 44% (TP53), 35% (CTNNB1), 31% (ARID1A), and 12% (MYC) of the assessed genes. However, these alterations have not been targeted by therapies and precision medicine has not been well-established in patients with HCC. Although some tumor-agnostic gene alterations, including changes in NTRK and MET, lead to precision medicine, the incidences of these genes are low (2–4% for NTRK and 2% for MET) [4,5][4][5].

4.1. Telomerase Reverse Transcriptase: TERT

TERT is one of the most common driver oncogenes of HCC with respect to cancer cell immortality. Every time cells divide, the recurrent arrangements at the edge of the chromosomes become shorter, and when the telomere length is shortened to a decided extent, the cells die. Cancer cells can be immortalized because of the high telomerase activity, which maintains the telomere length. TERT codes a telomerase subunit and affects the regulation of telomerase activity, causing the oncogenic progression of various cancers. HCCs have a 50% point mutation in the promotor area that regulates the TERT gene expression. Although drugs targeted for TERT treatment are being developed, their efficacy has not yet been established [4,5][4][5].

4.2. TP53

TP53 is one of the most effective tumor suppressing genes [46][30]. TP53 mutations are found in various human cancers [47,48][31][32]. Point mutations of the gene were found in ~40% of HCC. The protein product of TP53, p53, functions as a transcription factor, suppresses transcription genes concerned with cell proliferation, and is called the “Guardian Deity of Genome.” The inactivation of p53 leads to genome instability and accumulates genome abnormalities that lead to oncogenesis. However, precision medicine based on the TP53 mutation has not yet been well established [4,5][4][5].

4.3. Wnt/βcatenin Signaling Pathway

The Wnt/βcatenin signaling pathway is important for organogenesis, maintenance of stem cells, adjustment of cell proliferation, movement, and polarity [49][33]. Alterations of this pathway were found in 40–50% of HCCs [21][34]. Most of these changes are point mutations of CTNNB1 exon3 that are responsible for CTNNB1 transfer into the nucleus. The mutations can activate MYC and CTNNDI, causing the proliferation of HCC cells [21][34]. This pathway alteration is also strongly related to the immunological properties of the tumor and might lead to a response to immunological therapy [50][35].

5. Tumor-Agnostic Precision Medicine

Recently, the efficacy of the same drug against common genetic alterations in all types of cancer has been established. Here, we discuss microsatellite instability-high (MSI-H), tumor mutation burden-high (TMB-H), and NTRK fusions. Although there are several reports showing the possible tumor-agnostic precision medicines for hepatobiliary and pancreatic cancers, the evidence is not enough because of an insufficiency in the number of examined cases, and thus further examinations are awaited. The tumor-agnostic genetic alterations and treatment results for hepatobiliary and pancreatic cancers are summarized in Table 21. In addition to these treatments, it is noteworthy that the United States Food and Drug Administration (FDA) recently accelerated approval of tumor-agonistic therapy for solid tumors with BRAF mutation [51][36].
Table 21.
Tumor-agnostic biomarkers and treatment results for hepatobiliary and pancreatic cancers.
TMB-HNTRK
AlterationsMutations of MLH1, MSH2, MSH6, PMS2-Fusions
Prevalence

Whole cancers

Hepatobiliary pancreatic		[37]

5%

Around 2%		[38]

13%

4%		[39]

0.26% (87/33997)

BTC 0.34% (2/787), PDAC 0.25% (5/1492)
DrugsPembrolizumabPembrolizumabLarotrectinibEntrectinib
StudyPhase 2 KEYNOTE-158Phase 2 KEYNOTE-158Integrated analysis of three phase 1/2Integrated analysis of two phase 2 and one phase 1
Efficacy

Whole cancers

Hepatobiliary		[40]

☆ ORR 34.3% (80/233)

BTC 41% (9/22), PDAC 18% (4/22)		[41]

☆ ORR 29.4% (30/102)

no data		[42]

☆ ORR 79% (121/153)

ORR of BTC 50% (1/2); PDAC 50% (1/2)		[43]

☆ ORR 57 % (31/54)

ORR of BTC 100% (1/1); PDAC 67% (2/3)
 MSI-HTMB-HNTRK
AlterationsMutations of MLH1, MSH2, MSH6, PMS2-Fusions
Prevalence

Whole cancers

Hepatobiliary pancreatic		[52]

5%

Around 2%		[53]

13%

4%		[54]

0.26% (87/33997)

BTC 0.34% (2/787), PDAC 0.25% (5/1492)
DrugsPembrolizumabPembrolizumabLarotrectinibEntrectinib
StudyPhase 2 KEYNOTE-158Phase 2 KEYNOTE-158Integrated analysis of three phase 1/2Integrated analysis of two phase 2 and one phase 1
Efficacy

Whole cancers

Hepatobiliary		[55]

☆ ORR 34.3% (80/233)

BTC 41% (9/22), PDAC 18% (4/22)		[56]

☆ ORR 29.4% (30/102)

no data		[57]

☆ ORR 79% (121/153)

ORR of BTC 50% (1/2); PDAC 50% (1/2)		[58]

☆ ORR 57 % (31/54)

ORR of BTC 100% (1/1); PDAC 67% (2/3)
 MSI-H
Abbreviations: BTC, biliary tract cancer; ORR, objective response rate; PDAC, pancreatic ductal adenocarcinoma; and MSI-H, microsatellite instability-high. ☆ Primary endpoint.

5.1. Microsatellite Instability-High in MSI-H Abnormality Phenotype

Mismatch repair deficiency (dMMR), a DNA repair deficiency caused by MLH1, MSH2, MSH6, or PMS2 mutation, and accumulation of gene mutations, leads to oncogenesis. dMMR tends to make errors in duplicating sequences, repeating a microsatellite sequence from one to several times. When dMMRs are widely found in the genome, the abnormality status is called MSI-High (MSI-H). There are two methods to investigate MSI status: polymerase chain reaction and NGS-based methods [59]. The incidence of MSI-H in the assessed 11 cancer types was 5%, and that in hepatobiliary and pancreatic cancers was ~2% [52]. The effectiveness of immune checkpoint inhibitors (ICIs) against MSI-H tumors has already been established. This effectiveness is due to the abundant expression of a mutation-associated neoantigen, which facilitates the recognition of cancer cells by the immune system, a process that is defined as cancer surveillance [60,61]. onversely, Lynch syndrome should be excluded from the MSI-H patient cohort. Lynch syndrome is one of the best-known hereditary cancers; its phenotypes are colonic, endometrial, and urinary tract cancers [62].
Mismatch repair deficiency (dMMR), a DNA repair deficiency caused by MLH1, MSH2, MSH6, or PMS2 mutation, and accumulation of gene mutations, leads to oncogenesis. dMMR tends to make errors in duplicating sequences, repeating a microsatellite sequence from one to several times. When dMMRs are widely found in the genome, the abnormality status is called MSI-High (MSI-H). There are two methods to investigate MSI status: polymerase chain reaction and NGS-based methods [44]. The incidence of MSI-H in the assessed 11 cancer types was 5%, and that in hepatobiliary and pancreatic cancers was ~2% [37]. The effectiveness of immune checkpoint inhibitors (ICIs) against MSI-H tumors has already been established. This effectiveness is due to the abundant expression of a mutation-associated neoantigen, which facilitates the recognition of cancer cells by the immune system, a process that is defined as cancer surveillance [45][46]. onversely, Lynch syndrome should be excluded from the MSI-H patient cohort. Lynch syndrome is one of the best-known hereditary cancers; its phenotypes are colonic, endometrial, and urinary tract cancers [47].

5.2. Tumor Mutation Burden-High (TMB-H) Phenotypes

Accumulated mutations on somatic genes, tumor mutation burden (TMB), is defined as the number of single nucleotide variations per megabase [63]. Tumors with more than 10 mutations per megabase were defined as TMB-High (TMB-H) tumors [56]. TMB differs by cancer type [64], and the frequency of TMB-H cancers was reported at ~13% in 2589 cases of various cancers, with Bellini’s duct carcinoma at 4.0% (28/706) [53]. There is a correlation between TMB and ORR to ICI. PDAC is a cancer that shows the least TMB and ORR to ICI. Conversely, HCC shows moderate TMB and ORR [65]. An abundant expression of mutation-associated neoantigens contributes to the efficacy of ICI in TMB-H cancers, similar to MSI-H cancers.
Accumulated mutations on somatic genes, tumor mutation burden (TMB), is defined as the number of single nucleotide variations per megabase [48]. Tumors with more than 10 mutations per megabase were defined as TMB-High (TMB-H) tumors [41]. TMB differs by cancer type [49], and the frequency of TMB-H cancers was reported at ~13% in 2589 cases of various cancers, with Bellini’s duct carcinoma at 4.0% (28/706) [38]. There is a correlation between TMB and ORR to ICI. PDAC is a cancer that shows the least TMB and ORR to ICI. Conversely, HCC shows moderate TMB and ORR [50]. An abundant expression of mutation-associated neoantigens contributes to the efficacy of ICI in TMB-H cancers, similar to MSI-H cancers.

5.3. Neurotropic Tyrosine Receptor Kinase: NTRK

The TRK receptor families TRK A/B/C are coded by NTRK genes and transmit the signaling into the cells concerned with differentiations and activities of peripheral and central neural cells. When NTRK1/2/3 are fused with other genes, TRK 1/2/3 protein activates itself continuously and keeps sending the signals, causing oncogenesis of the cell [68]. The incidences of NTRK fusion in various tumor types are 0.26% and for BTC and PDAC is 0.34% and 0.25%, respectively [54]. Integrated analyses of three phase 1/2 studies—NCT02122913, NCT02637687, and NCT02576431—although it contained few BTCs and PDACs, showed the efficacy of larotrectinib.
The TRK receptor families TRK A/B/C are coded by NTRK genes and transmit the signaling into the cells concerned with differentiations and activities of peripheral and central neural cells. When NTRK1/2/3 are fused with other genes, TRK 1/2/3 protein activates itself continuously and keeps sending the signals, causing oncogenesis of the cell [51]. The incidences of NTRK fusion in various tumor types are 0.26% and for BTC and PDAC is 0.34% and 0.25%, respectively [39]. Integrated analyses of three phase 1/2 studies—NCT02122913, NCT02637687, and NCT02576431—although it contained few BTCs and PDACs, showed the efficacy of larotrectinib.

6. CGP by Liquid Biopsy

CGP by circulating tumor DNA (ctDNA) analysis is an established and clinically applied liquid biopsy technique [69,70][52][53]. Liquid biopsy, as a diagnostic procedure, has two breakthrough advantages as follows: (1) specimen collection procedure is relatively easy and provides real-time genetic information, and (2) turnaround time is short. Conversely, there are several negative points to remember. Firstly, when the amount of ctDNA is small, existing alterations might not be detected [71][54]. Secondly, the procedure is complicated by aging, which increases the incidence of false positives by clonal hematopoiesis of indeterminate potential (CHIP) [72,73][55][56]. The most commonly involved genes include DNMT3A, TET2, and ASXL1; however, other frequently mutated genes include TP53, JAK2, SF3B1, GNB1, PPM1D, GNAS, and BCORL1 [74,75,76][57][58][59]. Given the limited evidence, caution is needed when interpreting ctDNA variants in these genes. Finally, detecting copy number alterations or DNA fusions is occasionally difficult [69][52].
In biliary and pancreatic cancers with major genetic alterations, over a 90% concordance between histology and liquid biopsy was obtained using NGS panel testing [77][60]. Evaluation of MSI status by liquid biopsy has been reported [78][61]. Additionally, germline alterations, such as BRCA1/2 mutations in PDAC, were also detected by liquid biopsy. About 3% of germline-assumed alterations in 10,000 patients with PDAC were detected by analyzing ctDNA [79][62]. Compared with variant allele frequency of somatic mutations, that of germline mutations was ~50%; thus, it is relatively easy to distinguish them.

References

  1. Javle, M.; Bekaii-Saab, T.; Jain, A.; Wang, Y.; Kelley, R.K.; Wang, K.; Kang, H.C.; Catenacci, D.; Ali, S.; Krishnan, S.; et al. Biliary Cancer: Utility of next-Generation Sequencing for Clinical Management: Genomic Profiling of Biliary Tract Cancer. Cancer 2016, 122, 3838–3847.
  2. Valle, J.W.; Lamarca, A.; Goyal, L.; Barriuso, J.; Zhu, A.X. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov. 2017, 7, 943–962.
  3. Singhi, A.D.; George, B.; Greenbowe, J.R.; Chung, J.; Suh, J.; Maitra, A.; Klempner, S.J.; Hendifar, A.; Milind, J.M.; Golan, T.; et al. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted with Existing Drugs or Used as Biomarkers. Gastroenterology 2019, 156, 2242–2253.
  4. Ang, C.; Klempner, S.J.; Ali, S.M.; Madison, R.; Ross, J.S.; Severson, E.A.; Fabrizio, D.; Goodman, A.; Kurzrock, R.; Suh, J.; et al. Prevalence of Established and Emerging Biomarkers of Immune Checkpoint Inhibitor Response in Advanced Hepatocellular Carcinoma. Oncotarget 2019, 10, 4018–4025.
  5. Shibata, T.; Arai, Y.; Totoki, Y. Molecular Genomic Landscapes of Hepatobiliary Cancer. Cancer Sci. 2018, 109, 1282–1291.
  6. Mosele, F.; Remon, J.; Mateo, J.; Westphalen, C.B.; Barlesi, F.; Lolkema, M.P.; Normanno, N.; Scarpa, A.; Robson, M.; Meric-Bernstam, F.; et al. Recommendations for the Use of Next-Generation Sequencing (NGS) for Patients with Metastatic Cancers: A Report from the ESMO Precision Medicine Working Group. Ann. Oncol. 2020, 31, 1491–1505.
  7. Farshidfar, F.; Zheng, S.; Gingras, M.-C.; Newton, Y.; Shih, J.; Robertson, A.G.; Hinoue, T.; Hoadley, K.A.; Gibb, E.A.; Roszik, J.; et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep. 2017, 18, 2780–2794.
  8. Abou-Alfa, G.K.; Macarulla, T.; Javle, M.M.; Kelley, R.K.; Lubner, S.J.; Adeva, J.; Cleary, J.M.; Catenacci, D.V.; Borad, M.J.; Bridgewater, J.; et al. Ivosidenib in IDH1-Mutant, Chemotherapy-Refractory Cholangiocarcinoma (ClarIDHy): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. Lancet Oncol. 2020, 21, 796–807.
  9. Imamura, T. Physiological Functions and Underlying Mechanisms of Fibroblast Growth Factor (FGF) Family Members: Recent Findings and Implications for Their Pharmacological Application. Biol. Pharm. Bull. 2014, 37, 1081–1089.
  10. Tiong, K.H.; Mah, L.Y.; Leong, C.-O. Functional Roles of Fibroblast Growth Factor Receptors (FGFRs) Signaling in Human Cancers. Apoptosis 2013, 18, 1447–1468.
  11. Baselga, J.; Swain, S.M. Novel Anticancer Targets: Revisiting ERBB2 and Discovering ERBB3. Nat. Rev. Cancer 2009, 9, 463–475.
  12. Kim, H.H.; Sierke, S.L.; Koland, J.G. Epidermal Growth Factor-Dependent Association of Phosphatidylinositol 3-Kinase with the ErbB3 Gene Product. J. Biol. Chem. 1994, 269, 24747–24755.
  13. Olayioye, M.A. NEW EMBO MEMBERS’ REVIEW: The ErbB Signaling Network: Receptor Heterodimerization in Development and Cancer. EMBO J. 2000, 19, 3159–3167.
  14. Rowinsky, E.K. The ErbB Family: Targets for Therapeutic Development Against Cancer and Therapeutic Strategies Using Monoclonal Antibodies and Tyrosine Kinase Inhibitors. Annu. Rev. Med. 2004, 55, 433–457.
  15. Soltoff, S.P.; Carraway, K.L.; Prigent, S.A.; Gullick, W.G.; Cantley, L.C. ErbB3 Is Involved in Activation of Phosphatidylinositol 3-Kinase by Epidermal Growth Factor. Mol. Cell. Biol. 1994, 14, 3550–3558.
  16. Yarden, Y.; Sliwkowski, M.X. Untangling the ErbB Signalling Network. Nat. Rev. Mol. Cell Biol. 2001, 2, 127–137.
  17. Avruch, J. Ras Activation of the Raf Kinase: Tyrosine Kinase Recruitment of the MAP Kinase Cascade. Recent Prog. Horm. Res. 2001, 56, 127–155.
  18. Kolch, W. Meaningful Relationships: The Regulation of the Ras/Raf/MEK/ERK Pathway by Protein Interactions. Biochem. J. 2000, 351 Pt 2, 289–305.
  19. Peyssonnaux, C.; Eychène, A. The Raf/MEK/ERK Pathway: New Concepts of Activation. Biol. Cell 2001, 93, 53–62.
  20. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; et al. Mutations of the BRAF Gene in Human Cancer. Nature 2002, 417, 949–954.
  21. Subbiah, V.; Lassen, U.; Élez, E.; Italiano, A.; Curigliano, G.; Javle, M.; de Braud, F.; Prager, G.W.; Greil, R.; Stein, A.; et al. Dabrafenib plus Trametinib in Patients with BRAFV600E-Mutated Biliary Tract Cancer (ROAR): A Phase 2, Open-Label, Single-Arm, Multicentre Basket Trial. Lancet Oncol. 2020, 21, 1234–1243.
  22. Struewing, J.P.; Hartge, P.; Wacholder, S.; Baker, S.M.; Berlin, M.; McAdams, M.; Timmerman, M.M.; Brody, L.C.; Tucker, M.A. The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 1997, 336, 1401–1408.
  23. The UKGPCS Collaborators; Kote-Jarai, Z.; Leongamornlert, D.; Saunders, E.; Tymrakiewicz, M.; Castro, E.; Mahmud, N.; Guy, M.; Edwards, S.; O’Brien, L.; et al. BRCA2 Is a Moderate Penetrance Gene Contributing to Young-Onset Prostate Cancer: Implications for Genetic Testing in Prostate Cancer Patients. Br. J. Cancer 2011, 105, 1230–1234.
  24. Momozawa, Y.; Sasai, R.; Usui, Y.; Shiraishi, K.; Iwasaki, Y.; Taniyama, Y.; Parsons, M.T.; Mizukami, K.; Sekine, Y.; Hirata, M.; et al. Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants. JAMA Oncol. 2022, 8, 871–878.
  25. Golan, T.; Kindler, H.L.; Park, J.O.; Reni, M.; Macarulla, T.; Hammel, P.; Van Cutsem, E.; Arnold, D.; Hochhauser, D.; McGuinness, D.; et al. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. JCO 2020, 38, 1442–1454.
  26. Hong, D.S.; Fakih, M.G.; Strickler, J.H.; Desai, J.; Durm, G.A.; Shapiro, G.I.; Falchook, G.S.; Price, T.J.; Sacher, A.; Denlinger, C.S.; et al. KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors. N. Engl. J. Med. 2020, 383, 1207–1217.
  27. Heining, C.; Horak, P.; Uhrig, S.; Codo, P.L.; Klink, B.; Hutter, B.; Fröhlich, M.; Bonekamp, D.; Richter, D.; Steiger, K.; et al. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Cancer Discov. 2018, 8, 1087–1095.
  28. Aguirre, A.J. Oncogenic NRG1 Fusions: A New Hope for Targeted Therapy in Pancreatic Cancer. Clin. Cancer Res. 2019, 25, 4589–4591.
  29. Jonna, S.; Feldman, R.A.; Swensen, J.; Gatalica, Z.; Korn, W.M.; Borghaei, H.; Ma, P.C.; Nieva, J.J.; Spira, A.I.; Vanderwalde, A.M.; et al. Detection of NRG1 Gene Fusions in Solid Tumors. Clin. Cancer Res. 2019, 25, 4966–4972.
  30. Lane, D.P.; Lain, S. Therapeutic Exploitation of the P53 Pathway. Trends Mol. Med. 2002, 8, S38–S42.
  31. Béroud, C.; Soussi, T. The UMD-P53 Database: New Mutations and Analysis Tools: UMD-P53 DATABASE. Hum. Mutat. 2003, 21, 176–181.
  32. Hussain, S.P.; Harris, C.C. Molecular Epidemiology of Human Cancer: Contribution of Mutation Spectra Studies of Tumor Suppressor Genes. Cancer Res. 1998, 58, 4023–4037.
  33. Clevers, H.; Nusse, R. Wnt/β-Catenin Signaling and Disease. Cell 2012, 149, 1192–1205.
  34. Miyoshi, Y.; Iwao, K.; Nagasawa, Y.; Aihara, T.; Sasaki, Y.; Imaoka, S.; Murata, M.; Shimano, T.; Nakamura, Y. Activation of the β-CateninGene in Primary Hepatocellular Carcinomas by Somatic Alterations Involving Exon 3. Cancer Res. 1998, 58, 2524–2527.
  35. Sia, D.; Jiao, Y.; Martinez-Quetglas, I.; Kuchuk, O.; Villacorta-Martin, C.; Castro de Moura, M.; Putra, J.; Camprecios, G.; Bassaganyas, L.; Akers, N.; et al. Identification of an Immune-Specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology 2017, 153, 812–826.
  36. U.S. Food & Drug Administration (FDA). Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid (accessed on 22 July 2022).
  37. Le, D.T.; Durham, J.N.; Smith, K.N.; Wang, H.; Bartlett, B.R.; Aulakh, L.K.; Lu, S.; Kemberling, H.; Wilt, C.; Luber, B.S.; et al. Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade. Science 2017, 357, 409–413.
  38. Shao, C.; Li, G.; Huang, L.; Pruitt, S.; Castellanos, E.; Frampton, G.; Carson, K.R.; Snow, T.; Singal, G.; Fabrizio, D.; et al. Prevalence of High Tumor Mutational Burden and Association with Survival in Patients With Less Common Solid Tumors. JAMA Netw. Open 2020, 3, e2025109.
  39. Solomon, J.P.; Linkov, I.; Rosado, A.; Mullaney, K.; Rosen, E.Y.; Frosina, D.; Jungbluth, A.A.; Zehir, A.; Benayed, R.; Drilon, A.; et al. NTRK Fusion Detection across Multiple Assays and 33,997 Cases: Diagnostic Implications and Pitfalls. Mod. Pathol. 2020, 33, 38–46.
  40. Marabelle, A.; Le, D.T.; Ascierto, P.A.; Di Giacomo, A.M.; De Jesus-Acosta, A.; Delord, J.-P.; Geva, R.; Gottfried, M.; Penel, N.; Hansen, A.R.; et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. JCO 2020, 38, 1–10.
  41. Marabelle, A.; Fakih, M.; Lopez, J.; Shah, M.; Shapira-Frommer, R.; Nakagawa, K.; Chung, H.C.; Kindler, H.L.; Lopez-Martin, J.A.; Miller, W.H.; et al. Association of Tumour Mutational Burden with Outcomes in Patients with Advanced Solid Tumours Treated with Pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study. Lancet Oncol. 2020, 21, 1353–1365.
  42. Drilon, A.; Laetsch, T.W.; Kummar, S.; DuBois, S.G.; Lassen, U.N.; Demetri, G.D.; Nathenson, M.; Doebele, R.C.; Farago, A.F.; Pappo, A.S.; et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children. N. Engl. J. Med. 2018, 378, 731–739.
  43. Doebele, R.C.; Drilon, A.; Paz-Ares, L.; Siena, S.; Shaw, A.T.; Farago, A.F.; Blakely, C.M.; Seto, T.; Cho, B.C.; Tosi, D.; et al. Entrectinib in Patients with Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1–2 Trials. Lancet Oncol. 2020, 21, 271–282.
  44. Eso, Y.; Shimizu, T.; Takeda, H.; Takai, A.; Marusawa, H. Microsatellite Instability and Immune Checkpoint Inhibitors: Toward Precision Medicine against Gastrointestinal and Hepatobiliary Cancers. J. Gastroenterol. 2020, 55, 15–26.
  45. Le, D.T.; Uram, J.N.; Wang, H.; Bartlett, B.R.; Kemberling, H.; Eyring, A.D.; Skora, A.D.; Luber, B.S.; Azad, N.S.; Laheru, D.; et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 2015, 372, 2509–2520.
  46. Dudley, J.C.; Lin, M.-T.; Le, D.T.; Eshleman, J.R. Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin. Cancer Res. 2016, 22, 813–820.
  47. Latham, A.; Srinivasan, P.; Kemel, Y.; Shia, J.; Bandlamudi, C.; Mandelker, D.; Middha, S.; Hechtman, J.; Zehir, A.; Dubard-Gault, M.; et al. Microsatellite Instability Is Associated with the Presence of Lynch Syndrome Pan-Cancer. JCO 2019, 37, 286–295.
  48. Chalmers, Z.R.; Connelly, C.F.; Fabrizio, D.; Gay, L.; Ali, S.M.; Ennis, R.; Schrock, A.; Campbell, B.; Shlien, A.; Chmielecki, J.; et al. Analysis of 100,000 Human Cancer Genomes Reveals the Landscape of Tumor Mutational Burden. Genome Med. 2017, 9, 34.
  49. Lawrence, M.S.; Stojanov, P.; Polak, P.; Kryukov, G.V.; Cibulskis, K.; Sivachenko, A.; Carter, S.L.; Stewart, C.; Mermel, C.H.; Roberts, S.A.; et al. Mutational Heterogeneity in Cancer and the Search for New Cancer-Associated Genes. Nature 2013, 499, 214–218.
  50. Yarchoan, M.; Hopkins, A.; Jaffee, E.M. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N. Engl. J. Med. 2017, 377, 2500–2501.
  51. Vaishnavi, A.; Le, A.T.; Doebele, R.C. TRKing Down an Old Oncogene in a New Era of Targeted Therapy. Cancer Discov. 2015, 5, 25–34.
  52. Merker, J.D.; Oxnard, G.R.; Compton, C.; Diehn, M.; Hurley, P.; Lazar, A.J.; Lindeman, N.; Lockwood, C.M.; Rai, A.J.; Schilsky, R.L.; et al. Circulating Tumor DNA Analysis in Patients with Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J. Clin. Oncol. 2018, 36, 1631–1641.
  53. Sunami, K.; Bando, H.; Yatabe, Y.; Naito, Y.; Takahashi, H.; Tsuchihara, K.; Toyooka, S.; Mimori, K.; Kohsaka, S.; Uetake, H.; et al. Appropriate Use of Cancer Comprehensive Genome Profiling Assay Using Circulating Tumor DNA. Cancer Sci. 2021, 112, 3911–3917.
  54. Bettegowda, C.; Sausen, M.; Leary, R.J.; Kinde, I.; Wang, Y.; Agrawal, N.; Bartlett, B.R.; Wang, H.; Luber, B.; Alani, R.M.; et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Sci. Transl. Med. 2014, 6, 224ra24.
  55. Krimmel, J.D.; Schmitt, M.W.; Harrell, M.I.; Agnew, K.J.; Kennedy, S.R.; Emond, M.J.; Loeb, L.A.; Swisher, E.M.; Risques, R.A. Ultra-Deep Sequencing Detects Ovarian Cancer Cells in Peritoneal Fluid and Reveals Somatic TP53 Mutations in Noncancerous Tissues. Proc. Natl. Acad. Sci. USA 2016, 113, 6005–6010.
  56. Fernandez-Cuesta, L.; Perdomo, S.; Avogbe, P.H.; Leblay, N.; Delhomme, T.M.; Gaborieau, V.; Abedi-Ardekani, B.; Chanudet, E.; Olivier, M.; Zaridze, D.; et al. Identification of Circulating Tumor DNA for the Early Detection of Small-Cell Lung Cancer. EBioMedicine 2016, 10, 117–123.
  57. Jaiswal, S.; Fontanillas, P.; Flannick, J.; Manning, A.; Grauman, P.V.; Mar, B.G.; Lindsley, R.C.; Mermel, C.H.; Burtt, N.; Chavez, A.; et al. Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. N. Engl. J. Med. 2014, 371, 2488–2498.
  58. Genovese, G.; Kähler, A.K.; Handsaker, R.E.; Lindberg, J.; Rose, S.A.; Bakhoum, S.F.; Chambert, K.; Mick, E.; Neale, B.M.; Fromer, M.; et al. Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence. N. Engl. J. Med. 2014, 371, 2477–2487.
  59. Xie, M.; Lu, C.; Wang, J.; McLellan, M.D.; Johnson, K.J.; Wendl, M.C.; McMichael, J.F.; Schmidt, H.K.; Yellapantula, V.; Miller, C.A.; et al. Age-Related Mutations Associated with Clonal Hematopoietic Expansion and Malignancies. Nat. Med. 2014, 20, 1472–1478.
  60. Zill, O.A.; Greene, C.; Sebisanovic, D.; Siew, L.M.; Leng, J.; Vu, M.; Hendifar, A.E.; Wang, Z.; Atreya, C.E.; Kelley, R.K.; et al. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015, 5, 1040–1048.
  61. Willis, J.; Lefterova, M.I.; Artyomenko, A.; Kasi, P.M.; Nakamura, Y.; Mody, K.; Catenacci, D.V.T.; Fakih, M.; Barbacioru, C.; Zhao, J.; et al. Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clin. Cancer Res. 2019, 25, 7035–7045.
  62. Slavin, T.P.; Banks, K.C.; Chudova, D.; Oxnard, G.R.; Odegaard, J.I.; Nagy, R.J.; Tsang, K.W.K.; Neuhausen, S.L.; Gray, S.W.; Cristofanilli, M.; et al. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. JCO 2018, 36, 3459–3465.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Video Production Service
Feedback